Retatrutide and the Future of Cardiometabolic Medicine Retatrutide represents a new era in cardiometabolic disease: one drug, multiple pathways, broad benefits
Overall, compared with the large and growing amount of pre-clinical and mechanistic evidence highlighting the reward-modulating and thus potentially anti-addictive properties of GLP-1RAs, only a few studies have investigated thus far the potential use of these medications in clinical populations with alcohol- or other substance-use disorders
Cost and insurance-related barriers are the most common reasons people stop taking GLP-1s, according to research by Gasoyan's team
Over the last few years, GLP-1 receptor agonists like semaglutide and tirzepatide have become household names in metabolic health, weight loss, and diabetes care
Shaking creates foam and can damage the peptide bonds
Research-grade retatrutide available from peptide suppliers is synthesized by third-party manufacturers and is not the same material used in Eli Lilly clinical trials
